CASI Pharmaceuticals Inc. (NASDAQ:CASI) traded with a subtraction of -$0.05 to $1.17 on Wednesday, a downside of -4.11 percent. An average of 1,278,604 shares of common stock have been traded in the last five days. There was a fall of -$0.0150 in the past week. The last 20 days have seen an average of 3,816,921 shares traded, while the 50-day average volume stands at 2,671,962.
CASI stock has decreased by -24.69% in the last month. The company shares reached their 1-month lowest point of $1.1500 on 10/06/21. With the stock rallying to its 52-week high on 01/26/21, shares of the company touched a low of $1.13 and a high of $3.90 in 52 weeks. In spite of this, the price is down -70.00% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
CASI Pharmaceuticals Inc. (CASI) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.63 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 0.32. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 7.56, the price-to-book (PB) ratio at 1.79.
The quick ratio of CASI Pharmaceuticals Inc. for the three months ended June 29 was 8.00, and the current ratio was 8.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.02 for the quarter ending June 29. CASI Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -201.47%. Its gross profit as reported stood at $5.63 million compared to revenue of $15.14 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CASI Pharmaceuticals Inc.’s return on assets was -37.50%, compared to -49.5% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, CASI Pharmaceuticals Inc. had $12.59 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $7.16 million in the quarter, while revenues of $5.74 million were grew 62.71%. The analyst consensus anticipated CASI Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.07 per share, but it turned out to be -$0.05, a 28.60% surprise. For the quarter, EBITDA amounted to -$7.51 million. Shareholders own equity worth $139.8 million.
From a technical analysis perspective, let’s take a brief look at CASI Pharmaceuticals Inc. (CASI) price momentum. RSI 9-day as of the close on 05 October was 33.37%, suggesting the stock is Neutral, with historical volatility in this time frame at 36.27%.
As of today, CASI’s price is $1.1970 -1.27% or -$0.0150 from its 5-day moving average. CASI is currently trading -27.19% lower than its 20-day SMA and -19.66% lower than its 100-day SMA. However, the stock’s current price level is -0.43% below the SMA50 and -58.09% below the SMA200.
The stochastic %K and %D were 7.96% and 8.73%, respectively, and the average true range (ATR) was 0.0823. With the 14-day stochastic at 4.17% and the average true range at 0.0906, the RSI (14) stands at 37.16%. The stock has reached -0.0167 on the 9-day MACD Oscillator while the 14-day reading was at -0.0473.
BTIG Research launched coverage on CASI Pharmaceuticals Inc. (NASDAQ: CASI) in its analyst report released on May 18, 2021. The firm assigned the stock a a Buy rating.The consensus rating for CASI Pharmaceuticals Inc. (CASI) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CASI, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is CASI’s price target for the next 12 months?
Analysts predict a range of price targets between $3.80 and $6.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for CASI Pharmaceuticals Inc. (CASI) stock is $4.45.